Actively Recruiting
Investigation of TAK-411 Treatment via IV Infusion in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy CIDP to Assess Safety and Functional Impact
Led by Takeda · Updated on 2026-11-03
36
Participants Needed
22
Research Sites
27 weeks
Total Duration
AI-Summary
What This Trial Is About
Chronic Inflammatory Demyelinating Polyradiculoneuropathy CIDP is an autoimmune disorder where the immune system attacks the protective covering of nerves, called myelin, leading to muscle weakness and loss of sensation in the arms and legs. This research is evaluating TAK-411, a modified immune globulin G made from human plasma, to see if it can reduce inflammation and improve symptoms in adults with CIDP. The main goal is to assess how TAK-411 affects physical functioning compared to a placebo group from a previous trial. Participants will receive TAK-411 through intravenous IV infusions. Initially, a 400 mgkg induction dose is given on Day 1, which may be repeated once after 3 weeks if no clinical change is seen. Following this, participants receive 200 mgkg IV infusions every 3 weeks for 24 weeks during the initial treatment period. Afterward, there is an optional extended treatment period lasting an additional 27 weeks. Participants may be treated with TAK-411 for up to 51 weeks and followed for 3 weeks after their last dose. During the study, participants may visit the clinic up to approximately 21 times. Various assessments will track functional ability and neurological status at multiple time points, including weeks 12, 24, and 54. Researchers will monitor changes using measures like the INCAT score, I-RODS score, hand grip strength, and adverse events. Safety and tolerability of TAK-411 will also be evaluated throughout the treatment and follow-up periods.
CONDITIONS
Brief Title
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Research Team
T
Takeda Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here